272 related articles for article (PubMed ID: 23409180)
21. Overexpression of B7-H3 in CD133+ colorectal cancer cells is associated with cancer progression and survival in human patients.
Bin Z; Guangbo Z; Yan G; Huan Z; Desheng L; Xueguang Z
J Surg Res; 2014 May; 188(2):396-403. PubMed ID: 24630518
[TBL] [Abstract][Full Text] [Related]
22. [Expressions of WWOX and CD133 in colorectal cancer and their clinical significance].
Zhu B; Wang D; Zhang Q; Wu S; Yu L; Tao Y
Nan Fang Yi Ke Da Xue Xue Bao; 2015 Nov; 35(11):1586-90. PubMed ID: 26607080
[TBL] [Abstract][Full Text] [Related]
23. Targeting CD133high Colorectal Cancer Cells In Vitro and In Vivo With an Asymmetric Bispecific Antibody.
Zhao L; Yang Y; Zhou P; Ma H; Zhao X; He X; Wang T; Zhang J; Liu Y; Zhang T
J Immunother; 2015; 38(6):217-28. PubMed ID: 26049545
[TBL] [Abstract][Full Text] [Related]
24. CD133 mRNA expression and microsatellite instability in colorectal carcinoma.
Huh JW; Park YS; Lee JH; Kim HR; Shin MG; Kim YJ
J Surg Oncol; 2010 Dec; 102(7):765-70. PubMed ID: 20872808
[TBL] [Abstract][Full Text] [Related]
25. Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis.
Wu H; Qi XW; Yan GN; Zhang QB; Xu C; Bian XW
PLoS One; 2014; 9(6):e100168. PubMed ID: 24940615
[TBL] [Abstract][Full Text] [Related]
26. Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer.
Galizia G; Gemei M; Del Vecchio L; Zamboli A; Di Noto R; Mirabelli P; Salvatore F; Castellano P; Orditura M; De Vita F; Pinto M; Pignatelli C; Lieto E
Arch Surg; 2012 Jan; 147(1):18-24. PubMed ID: 22250106
[TBL] [Abstract][Full Text] [Related]
27. CD133 expression is correlated with poor prognosis in colorectal cancer.
Kashihara H; Shimada M; Kurita N; Iwata T; Sato H; Kozo Yoshikawa ; Higashijima J; Chikakiyo M; Nishi M; Matsumoto N
Hepatogastroenterology; 2014 Sep; 61(134):1563-7. PubMed ID: 25436343
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis.
Li X; Zhao H; Gu J; Zheng L
Int J Clin Exp Pathol; 2015; 8(10):12084-92. PubMed ID: 26722393
[TBL] [Abstract][Full Text] [Related]
29. Differential expression of CD133 based on microsatellite instability status in human colorectal cancer.
Park JJ; Kwon JH; Oh SH; Choi J; Moon CM; Ahn JB; Hong SP; Cheon JH; Kim TI; Kim H; Kim WH
Mol Carcinog; 2014 Feb; 53 Suppl 1():E1-10. PubMed ID: 23065858
[TBL] [Abstract][Full Text] [Related]
30. The most reliable surface marker for the identification of colorectal cancer stem-like cells: A systematic review and meta-analysis.
Abbasian M; Mousavi E; Arab-Bafrani Z; Sahebkar A
J Cell Physiol; 2019 Jun; 234(6):8192-8202. PubMed ID: 30317669
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of CD133 expression in stage I lung adenocarcinomas.
Woo T; Okudela K; Mitsui H; Yazawa T; Ogawa N; Tajiri M; Yamamoto T; Rino Y; Kitamura H; Masuda M
Int J Clin Exp Pathol; 2010 Dec; 4(1):32-42. PubMed ID: 21228926
[TBL] [Abstract][Full Text] [Related]
32. Predictive value of cancer stem-like cells and cancer-associated genetic markers for peritoneal recurrence of colorectal cancer in patients after curative surgery.
Nakamura K; Iinuma H; Aoyagi Y; Shibuya H; Watanabe T
Oncology; 2010; 78(5-6):309-15. PubMed ID: 20616575
[TBL] [Abstract][Full Text] [Related]
33. The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancer.
Elsaba TM; Martinez-Pomares L; Robins AR; Crook S; Seth R; Jackson D; McCart A; Silver AR; Tomlinson IP; Ilyas M
PLoS One; 2010 May; 5(5):e10714. PubMed ID: 20502714
[TBL] [Abstract][Full Text] [Related]
34. CD 133+ and CXCR4+ colon cancer cells as a marker for lymph node metastasis.
Silinsky J; Grimes C; Driscoll T; Green H; Cordova J; Davis NK; Li L; Margolin DA
J Surg Res; 2013 Nov; 185(1):113-8. PubMed ID: 23777983
[TBL] [Abstract][Full Text] [Related]
35. Expression of CD133 is associated with poor prognosis in stage II colorectal carcinoma.
Park YY; An CH; Oh ST; Chang ED; Lee J
Medicine (Baltimore); 2019 Aug; 98(32):e16709. PubMed ID: 31393377
[TBL] [Abstract][Full Text] [Related]
36. AC133 expression associated with poor prognosis in stage II colorectal cancer.
Ying X; Wu J; Meng X; Zuo Y; Xia Q; Chen J; Feng Y; Liu R; Li L; Huang W
Med Oncol; 2013 Mar; 30(1):356. PubMed ID: 23322518
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.
Zhao P; Lu Y; Jiang X; Li X
Cancer Sci; 2011 May; 102(5):1107-11. PubMed ID: 21276138
[TBL] [Abstract][Full Text] [Related]
38. Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis.
Li C; Liu T; Yin L; Zuo D; Lin Y; Wang L
Medicine (Baltimore); 2019 Mar; 98(9):e14659. PubMed ID: 30817589
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of stem cell marker CD133 expression in colorectal cancer.
Wang BB; Li ZJ; Zhang FF; Hou HT; Yu JK; Li F
Histol Histopathol; 2016 Mar; 31(3):299-306. PubMed ID: 26442717
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of CD44 variant 2 upregulation in colorectal cancer.
Ozawa M; Ichikawa Y; Zheng YW; Oshima T; Miyata H; Nakazawa K; Guan HB; Shiozawa M; Akaike M; Watanabe K; Ota M; Fujii S; Kunisaki C; Ishikawa T; Tanaka K; Akiyama H; Endo I; Taniguchi H
Br J Cancer; 2014 Jul; 111(2):365-74. PubMed ID: 24921913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
